Received Nov 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | — | — |
No additional AE/no PQC.; Nurse called and reported inadvertent administration of VARIVAX on 09OCT2025 and administration of MMR-II on 23OCT2025 to the same patient. No additional information was known by reporter at time of call. No additional AE/no PQC.; This spontaneous report was received from nurse and refers to a 15-month-old patient of unreported gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 09-Oct-2025, the patient was vaccinated with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) as prophylaxis (lot # and expiration date were not reported) reconstituted with sterile diluent (doses, scheme, route of administration, lot number and expiration dates not reported) On 23-OCT-2025, there was an inadvertent administration of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) reconstituted with sterile diluent (dose, route of administration, scheme, lot number, expiration date and indication were not provided) (Inappropriate schedule of product administration). No additional information was known by reporter at time of call. No additional adverse events (AE)/no product quality complaints reported (PQC).
Sterile diluent